Published in Leukemia on June 10, 2010
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol (2013) 1.66
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52
Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev (2012) 1.43
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res (2012) 1.33
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol (2014) 1.28
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Invest New Drugs (2011) 1.25
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst (2011) 1.23
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk Lymphoma (2013) 1.21
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood (2012) 1.21
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica (2011) 1.14
FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol (2011) 1.09
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res (2012) 1.06
Nexavar/Stivarga and viagra interact to kill tumor cells. J Cell Physiol (2015) 1.06
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist (2011) 1.05
Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res (2011) 0.97
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. J Cell Physiol (2015) 0.96
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol (2013) 0.95
Ontogeny and sorafenib metabolism. Clin Cancer Res (2012) 0.92
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs (2014) 0.91
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget (2016) 0.88
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol (2014) 0.87
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. J Cell Physiol (2015) 0.87
Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol (2015) 0.87
'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J (2016) 0.86
Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? Curr Opin Hematol (2014) 0.84
Will newer tyrosine kinase inhibitors have an impact in AML? Best Pract Res Clin Haematol (2010) 0.83
NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Leukemia (2015) 0.79
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs (2012) 0.79
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs (2011) 0.79
Sorafenib in combination with low-dose-homoharringtonine as a salvage therapy in primary refractory FLT3-ITD-positive AML: a case report and review of literature. Int J Clin Exp Med (2015) 0.76
Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia. Clin Med Insights Oncol (2012) 0.76
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol (2017) 0.75
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. Int J Mol Sci (2016) 0.75
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia. Blood Cancer J (2014) 0.75
How I treat FLT3-mutated AML. Blood (2016) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. ACS Omega (2017) 0.75
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
Drug therapy for acute myeloid leukemia. Blood (2005) 3.74
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet (1992) 2.88
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood (2009) 2.82
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res (2005) 2.76
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer (2005) 2.49
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood (2009) 2.44
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood (2006) 2.18
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood (2004) 2.03
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood (2008) 1.90
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol (2005) 1.58
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem (2007) 1.51
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.47
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia (2005) 1.44
Drug elimination and apparent volume of distribution in multicompartment systems. J Pharm Sci (1972) 1.43
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie (2002) 1.39
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood (2004) 1.30
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood (2004) 1.27
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood (2005) 1.20
Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res (2008) 1.19
Sorafenib. Expert Opin Pharmacother (2006) 1.19
In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol (2004) 1.17
Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol (2008) 1.09
Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom (2006) 0.98
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
Neurogenesis in the adult is involved in the formation of trace memories. Nature (2001) 8.13
Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell (1985) 7.29
Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 5.55
The AGAMOUS-LIKE 20 MADS domain protein integrates floral inductive pathways in Arabidopsis. Genes Dev (2000) 3.90
Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J (1993) 3.85
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Determinants of genital human papillomavirus detection in a US population. J Infect Dis (2001) 3.21
Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc Natl Acad Sci U S A (1987) 3.18
Imaging the surface of Altair. Science (2007) 3.03
Dendrimer-encapsulated metal nanoparticles: synthesis, characterization, and applications to catalysis. Acc Chem Res (2001) 2.85
Nature of the collagen synthesized by a transplanted chondrosarcoma. Arch Biochem Biophys (1975) 2.64
Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol (2000) 2.61
Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem (1997) 2.47
Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med (2001) 2.47
PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J (1998) 2.44
Comparison of open and laparoscopic live donor nephrectomy. Ann Surg (1997) 2.43
OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther (2012) 2.43
Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A (1994) 2.41
Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood (1998) 2.31
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Production of procollagen by human fibroblasts in culture. Proc Natl Acad Sci U S A (1972) 2.30
Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. J Biol Chem (2000) 2.26
Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res (2000) 2.21
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19
Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med (1995) 2.15
Dysgonic fermenter 3-associated gastrointestinal disease in a patient with common variable hypogammaglobulinemia. Am J Med (1988) 2.05
Palmitoylation is required for signaling functions and membrane attachment of Gq alpha and Gs alpha. J Biol Chem (1993) 2.02
Automated blood pressure measurements in laboring women: are they reliable? Am J Obstet Gynecol (1993) 2.01
Acute bilineal leukemia: a rare disease with poor outcome. Leukemia (2007) 1.98
Studies in relation to biosynthesis. XLII. The structural elucidation and some aspects of the biosynthesis of the brevianamides-A and -E. Tetrahedron (1970) 1.95
The recovery of cognitive function after general anesthesia in elderly patients: a comparison of desflurane and sevoflurane. Anesth Analg (2001) 1.92
Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol (2000) 1.88
A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. Transplantation (1999) 1.88
Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol (1996) 1.82
Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol (1986) 1.82
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1987) 1.82
Climate change and the integrity of science. Science (2010) 1.80
Sphingosine-induced apoptosis is dependent on lysosomal proteases. Biochem J (2001) 1.80
Ophthalmic manifestations of leukemia. Arch Ophthalmol (1989) 1.75
Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia (2006) 1.74
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood (2001) 1.73
p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med (2001) 1.73
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 1.68
Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol (1995) 1.68
Identification of the collagenous proteins synthesized by cultured cells from human skin. Biochemistry (1975) 1.67
Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med (1986) 1.64
Increasing access and providing social services to improve drug abuse treatment for women with children. Addiction (2000) 1.63
Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology (1995) 1.62
Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy. J Natl Cancer Inst (1996) 1.60
A maternal diet high in n - 6 polyunsaturated fats alters mammary gland development, puberty onset, and breast cancer risk among female rat offspring. Proc Natl Acad Sci U S A (1997) 1.60
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Prediction of electroencephalographic spectra from neurophysiology. Phys Rev E Stat Nonlin Soft Matter Phys (2001) 1.58
The amplitude and time course of the myoplasmic free [Ca2+] transient in fast-twitch fibers of mouse muscle. J Gen Physiol (1996) 1.58
Big mitogen-activated kinase regulates multiple members of the MEF2 protein family. J Biol Chem (2000) 1.57
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
Population differences in SLE susceptibility genes: STAT4 and BLK, but not PXK, are associated with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun (2009) 1.55
Using pentafluorophenyl as a Lewis acid to stabilize a cis secondary amide conformation. Org Lett (2001) 1.55
Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif (2009) 1.55
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia (2006) 1.51
Proliferative activity of calcifying odontogenic cysts as evaluated by proliferating cell nuclear antigen labeling index. Pathol Int (1998) 1.51
Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med (1998) 1.51
Cusum as an aid to early assessment of the surgical trainee. Br J Surg (1995) 1.51
Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem (1993) 1.50
Subcellular [Ca2+]i gradients during excitation-contraction coupling in newborn rabbit ventricular myocytes. Circ Res (1999) 1.50
Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol (2009) 1.47
Origins of agriculture in eastern north america. Science (1989) 1.47
Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T lymphocytes. J Exp Med (1997) 1.47
The effects of differing resistance training modes on the preservation of bone mineral density in postmenopausal women: a meta-analysis. Osteoporos Int (2015) 1.47
Leukemic retinopathy. Relationship between fundus lesions and hematologic parameters at diagnosis. Ophthalmology (1989) 1.46
Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10) Br J Haematol (1990) 1.45
The secondary leukemias: challenges and research directions. J Natl Cancer Inst (1996) 1.45
Evaluation of a rapid immunoturbidimetric assay for opsonic fibronectin in surgical and trauma patients. J Lab Clin Med (1981) 1.44
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption. Arch Dermatol (1991) 1.44
Defect in SHAP-hyaluronan complex causes severe female infertility. A study by inactivation of the bikunin gene in mice. J Biol Chem (2001) 1.42
Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst (1991) 1.42
Image reconstruction from cone-beam projections: necessary and sufficient conditions and reconstruction methods. IEEE Trans Med Imaging (1985) 1.42
Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin. J Natl Cancer Inst (1999) 1.42
Identification and characterization of circulating prostate carcinoma cells. Cancer (2000) 1.41
Serine protease inhibitor-6 differentially affects the survival of effector and memory alloreactive CD8-T cells. Am J Transplant (2015) 1.41
Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem (1992) 1.41
Shades of gray matter: noninvasive optical images of human brain responses during visual stimulation. Psychophysiology (1995) 1.41
Disseminated infection with Trichosporon beigelii. Rev Infect Dis (1988) 1.40
The role of 99Tcm-HMPAO white cell imaging in suspected orthopaedic infection. Br J Radiol (1992) 1.39
Detection of clonal B cell populations in paraffin-embedded tissues by polymerase chain reaction. Am J Pathol (1993) 1.38
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res (2001) 1.37
Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol (1987) 1.37
Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res (2001) 1.36
Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis (1988) 1.36
Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response. Int Immunol (1995) 1.35
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res (2001) 1.34